Drugs / Re-Q Pro-Longevity Serum
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07686198 Comparator | Jul → Nov 2026 expected | — | Goldman, Butterwick, Fitzpatrick and Groff | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Re-Q Pro-Longevity Serum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07686198 ↗ |
| Route | Topical | “Participants will apply the study product to the bilateral dorsal forearms after facial cleansing every morning and evening.” NCT07686198 ↗ |